Star Update Podcast - Cardiology News Summaries cover art

All Episodes

Star Update Podcast - Cardiology News Summaries — 240 episodes

#
Title
1

Heart Failure Outcomes with SGLT2 Inhibitors in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis

2

Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Systematic Review and Meta-Analysis

3

Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study

4

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials

5

Circadian variation in ST-segment elevation myocardial infarction: a nationwide analysis of onset, treatment delays, and culprit artery patterns

6

Impact of Early Percutaneous Coronary Intervention on Long-Term Survival in Patients With Acute Myocardial Infarction

7

Lower Ticagrelor Dosing in the Dual Antiplatelet Regimen for Neurointerventional Procedures

8

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study

9

Incidence and In-Hospital Outcomes of Bradycardia or Atrioventricular Conduction Disorder in Patients With Type 2 Myocardial Infarction: A Nationwide Inpatient Analysis

10

Pharmacological Evaluation of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin Pretreatment on Infarct Artery Flow in Patients with Acute STEMI

11

Intravascular imaging-guided percutaneous coronary intervention for acute myocardial infarction according to ACC/AHA lesion classification

12

β-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis

13

Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: a propensity score-matched analysis

14

Differential Impact of Metoprolol Formulations on Heart Failure Outcomes: A Multi-center Study

15

Prognostic Implications of Heart Failure Rehospitalization in Adults with CHD & Clinical Benefits of Medical Therapy

16

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure

17

Impact of digoxin versus beta-blocker in patients with coexistent atrial fibrillation and heart failure: a target trial emulation

18

Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation for Bioprosthetic Valve Failure

19

1-Month Versus 12-Month Dual Antiplatelet Therapy for Patients with Chronic Total Occlusion After Successful Percutaneous Coronary Intervention

20

Drug Utilization Patterns and Adherence to Guideline-Directed Therapy in Acute Myocardial Infarction: A Prospective Observational Study

21

The use of beta-blockers for heart failure with reduced ejection fraction in the era of SGLT2 inhibitors - are we still afraid to up-titrate?

22

Angiotensin receptor-neprilysin inhibitors and mortality among patients with heart failure with reduced ejection fraction

23

Comparison between clopidogrel and ticagrelor in CYP2C19 loss-of-function alleles coronary artery disease and stroke patients: a meta-analysis

24

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials

25

ST-elevation myocardial infarction and air pollution: relationship between hourly air pollution and cardiovascular risk factors

26

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

27

Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial

28

1-Month Versus 12-Month Dual Antiplatelet Therapy for Patients with Chronic Total Occlusion After Successful Percutaneous Coronary Intervention

29

Effects of moderate physical training program in post-myocardial infarction patients with arterial hypertension

30

Combined effects of clonal hematopoiesis of intermediate potential and P2Y12 inhibitors on outcomes of patients with ST-segment elevation myocardial infarction: A prospective study

31

Early β-Blocker Use and Clinical Outcomes in Acute Myocardial Injury: A Retrospective Cohort Study

32

A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion

33

Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: Key Recommendations

34

Pragmatic Use of Ticagrelor: Improving Outcomes in Medical Management of Acute Coronary Syndrome (PracTiCal India Study)

35

Exploring the Impact of Beta-Blockers Post-Acute Myocardial Infarction in Patients with Preserved Ejection Fraction: A Meta-Analysis

36

The 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Asian Perspective

37

Effect of Body Mass Index in Patients With Cardiogenic Shock Requiring Microaxial Flow Pump

38

The Impact of Preoperative P2Y12 Inhibitors on Short- and Long-Term Outcomes Following Percutaneous Coronary Intervention

39

Incidence and Risk Factors of De Novo Postpartum Hypertension: Understanding Links to Long-Term Cardiovascular Risk

40

Aspirin vs Clopidogrel vs Ticagrelor Monotherapy Compared to 12 Months of DAPT Following PCI; A Systematic Review and Meta-Analysis

41

Does Timing of Coronary Artery Bypass Grafting after ST-Elevation Myocardial Infarction Impact Early- and Long-Term Outcomes?

42

TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing PCI

43

In-hospital use of beta-blockers for critically ill patients with acute heart failure: Whether and when to initiate

44

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee

45

Impact of Metabolic Syndrome on Clinical Profile and Prognosis in Patients with Acute ST-Elevation Myocardial Infarction: a Cross-Sectional Study

46

Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction

47

1The “Silent Enemy” Called Renal Artery Stenosis: A Mini-Review:

48

Early β-Blocker Use and Clinical Outcomes in Acute Myocardial Injury: A Retrospective Cohort Study

49

Impact of controlled stepwise reperfusion during primary percutaneous coronary intervention on patients with ST-elevation myocardial infarction

50

Triglyceride glucose-waist circumference as a predictor of mortality and subtypes of cardiovascular disease: a systematic review and meta-analysis

51

The use of beta-blockers for heart failure with reduced ejection fraction in the era of SGLT2 inhibitors – are we still afraid to up-titrate?

52

De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials

53

TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial

54

Examining the Specificity of Smartphone ECG Devices in Decision-Making for ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction

55

Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events

56

Impact of beta-blocker up titration on patients after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation: The OCEAN-mitral registry

57

Intravascular imaging-guided percutaneous coronary intervention in patients with acute myocardial infarction and cardiogenic shock

58

Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

59

Impact of Adherence to Beta-Blockers in Patients With All-Comers ST-Segment Elevation Myocardial Infarction and According to Left Ventricular Ejection Fraction at Discharge: Results From FAST-STEMI

60

A comparison of the effects of ticagrelor and clopidogrel in patients with acute ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials

61

Contemporary Use of β-Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis

62

Guideline-directed medical therapy improves cell viability in an iPSC-derived cardiomyocyte hypoxia injury model

63

Exploring The Risks And Benefits of Upstream Loading of P2Y12 inhibitors In Acute Coronary Syndrome Patients

64

Ticagrelor monotherapy the way forward after Percutaneous Coronary Interventions: An updated meta-analysis

65

Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus

66

Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-Analysis

67

Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022)

68

Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review

69

Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial

70

2024 ESC Guidelines for Management of Chronic Coronary Syndromes: Key Points

71

2024 ESC Guidelines for Management of Elevated BP and Hypertension: Key Points

72

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation

73

Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials

74

Efficacy and Safety of P2Y12 monotherapy vs standard dual antiplatelet therapy DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials

75

Early postoperative beta-blockers are associated with improved cardiac output after late complete repair of tetralogy of Fallot: a retrospective cohort study

76

Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure

77

Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management

78

Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry

79

Ticagrelor downregulates the expression of proatherogenic and proinflammatory micro RNA 125-b compared to clopidogrel: A randomized, controlled trial

80

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1 , ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy

81

The new European Society of Cardiology acute coronary syndrome guideline and its impact in the CPU and emergency department setting

82

Coronary Atherosclerotic Plaque Activity and Risk of Myocardial Infarction

83

Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting trial

84

Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A analysis of TWILIGHT randomized clinical trial

85

Obesity is associated with acute kidney injury in ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention: A national representative cohort study

86

Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5

87

Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis

88

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT)

89

The application value of Metoprolol combined with Dagalizin in enhancing cardiac function and ventricular remodeling in patients with acute myocardial infarction after PCI.

90

Impact of cardiac rehabilitation on ventricular-arterial coupling and left ventricular function in patients with acute myocardial infarction

91

Prognostic Impact of Early Administration of β-Blockers in Critically Ill Patients with Acute Myocardial Infarction

92

Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention

93

ACC Expert Consensus statement 2024 for Treatment of HFrEF: Key Points

94

Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis

95

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial

96

Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis

97

The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting

98

A novel score to predict in-hospital mortality for patients with acute coronary syndrome and out-of-hospital cardiac arrest: the FACTOR study

99

Factors Associated With Myocardial Infarction in a Rural Population With Peripheral Arterial Diseases

100

Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

101

Ticagrelor versus Clopidogrel in Endovascular therapy for Cerebral Aneurysms: A Systematic Review and Meta-analysis

102

Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry

103

One year clinical outcome of dual anti-platelet therapy with the Novel Ticagrelor plus Aspirin versus Clopidogrel plus Aspirin for Endovascular Intervention of patients with Intracranial Aneurysm

104

The Prognostic impact of treatments evolution in STEMI

105

Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis

106

Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction

107

De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary Syndrome

108

Effect of beta-blockers and exercise restriction on the prevention of sudden cardiac death in pediatric hypertrophic cardiomyopathy

109

Emergent use of ticagrelor during endovascular reperfusion in large arterial occlusions

110

ARTESIA Study Indicates Apixaban Reduces Stroke Risk but Increases Bleeding in Subclinical AF

111

CARDIA-SSBP Study Reveals 6 mm Hg Blood Pressure Reduction in One Week with Low- Salt Diet

112

Bleeding Reduction in LVAD Patients with Aspirin Discontinuation: ARIES-HM3 Trial

113

Liberal Transfusion in Anemic MI Cases Shows Favorable Results: MINT Study

114

Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis

115

Sex and Age Differences of Major Cardiovascular Events in Patients After Percutaneous Coronary Intervention

116

Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After PCI

117

β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention

118

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction

119

Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

120

Factors associated with complications in ST-elevation myocardial infarction: a single-center experience

121

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention

122

Prognostic factors in young patients with ST-segment elevation myocardial infarction

123

Early Effects of Ticagrelor Versus Clopidogrel on Peripheral Endothelial Function After Non-ST-Elevation Acute Coronary Syndrome and Assessment of Its Relationship With Coronary Microvascular Function

124

Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention

125

Metoprolol or Verapamil in the Management of Patients With Hypertrophic Cardiomyopathy: A Systematic Review

126

2023 ESH Guideline for the Management of Hypertension with specific focus on Beta blockers

127

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events

128

Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction

129

Clinical risk factors and outcomes of young patients with acute ST segment elevation myocardial infarction: a retrospective study

130

Frequency of New Onset Atrial Fibrillation in Patients Presenting with ST-Segment Elevation Myocardial Infarction

131

The prognostic value of myocardial salvage index by cardiac magnetic resonance in ST-segment elevation myocardial infarction patients: a systematic review and meta-analysis.

132

Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction.

133

Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

134

Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction

135

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction

136

Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction

137

Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials

138

Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction without Heart Failure Undergoing Primary P

139

Safe and Effective Early Use of Betablockers after Pediatric Heart Transplantation

140

Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction

141

Ticagrelor Treatment is Associated With Increased Coronary Flow Reserve in Survivors of Myocardial Infarction

142

Sex-related bleeding risk in acute coronary syndrome patients receiving dual antiplatelet therapy with aspirin and a P2Y12 inhibitor

143

Effect of early metoprolol before PCI in ST-segment elevation myocardial infarction on infarct size and left ventricular ejection fraction. A systematic review and meta-analysis of clinical trials

144

Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials

145

Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series

146

Interventional therapy of acute coronary syndromes in very old patient population and results of 2 years follow-up

147

Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trials

148

A predictive model of response to metoprolol in children and adolescents with postural tachycardia syndrome

149

Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial

150

Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack

151

Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome

152

Role of β-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction

153

Baroreflex sensitivity predicts therapeutic effects of metoprolol on pediatric postural orthostatic tachycardia syndrome

154

Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease

155

The prognostic effect of ST-elevation in lead aVR on coronary artery disease, and outcome in acute coronary syndrome patients: a systematic review and meta-analysis

156

Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis

157

Efficacy of metoprolol plus atorvastatin for carotid atherosclerosis and its influence on carotid intima-media thickness and homocysteine level

158

Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis

159

Associations of systemic inflammation and social support with suicidal ideation in patients with acute coronary syndrome and stroke

160

Comparison of Rate Control Efficacy between beta-blockers and Calcium Channel Blockers in Patients Hospitalized with Atrial Fibrillation

161

Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart

162

A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke

163

Efficacy and Safety of Sustained-Release Metoprolol with Dronedarone After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis

164

Incidence and predictors of heart failure after acute coronary Syndrome: The CORALYS registry

165

Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy

166

Clopidogrel resistance and ticagrelor replacement in dual antiplatelet therapy for carotid artery stenting

167

Effect of early metoprolol before PCI in ST-segment elevation myocardial infarction on infarct size and left ventricular ejection fraction. A systematic review and meta-analysis of clinical trials

168

Safety and efficacy of dual antiplatelet therapy combining aspirin and ticagrelor in patients with undergoing intracranial stenting procedures

169

Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

170

Ticagrelor versus clopidogrel in reducing inflammatory cell infiltration of thrombus aspirated in patients with ST-elevation myocardial infarction

171

Beta-blockers in acute coronary syndrome: does rhythm matter?

172

Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy

173

Bleeding outcomes with ticagrelor versus clopidogrel in patients with the acute coronary syndrome; a focused analysis from the multicenter CREA ARIAM Andalucia registry

174

Conservative management in a contemporary cohort of patients with acute coronary syndrome: Results from the FORCE-ACS registryConservative management in a contemporary cohort of patients with acute co

175

Coronary Artery Embolism and Acute Coronary Syndrome: A critical appraisal of existing data Trends

176

Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy

177

Beta-blocker Use After Thoracic Endovascular Aortic Repair in Patients with Type B Aortic Dissection Is Associated with Improved Early Aortic Remodeling

178

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis

179

Management of acute coronary syndrome without ST-segment elevation

180

The impact of a comprehensive pharmaceutical care intervention in addition to cardiac rehabilitation program on outcomes of post-acute coronary syndrome patients: A pilot study

181

Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure

182

Comparative Safety and Effectiveness of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome: An On-Treatment Analysis from a Multicentre Registry

183

Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement

184

Efficacy and Safety of Ticagrelor Over Time in Patients with Prior MI in PEGASUS-TIMI 54

185

Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

186

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

187

Timing of Oral P2Y12 Inhibitor Administration in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome

188

Effect of Ticagrelor Monotherapy vs Ticagrelor with Aspirin on Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndrome: The TICO Randomized Clinical Trial

189

Low-Dose Triple Combination Antihypertensive Therapy vs Usual Care and Time at Target Blood Pressure

190

Initial Decline in eGFR After Dapagliflozin Initiation and Its Associated Outcomes in Patients with HFrEF

191

Elevated Lipoprotein(a) and Risk of Atrial Fibrillation

192

DAPT Discontinuation, Platelet Reactivity, and Adverse Outcomes After PCi

193

Oral Anticoagulant treatment and the risk of dementia in patients with atrial fibrillation.

194

The AMPLITUDE-O Trial : CVOT of Efpeglenatide, a new potent, exendin-4-based weekly subcutaneous GLP-1 receptor agonist

195

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

196

Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review

197

Tight control of blood pressure in pregnant women with non-severe hypertension: expectations for decreasing adverse maternal and fatal pregnancy outcomes

198

Effect of Chloride levels in HF therapy

199

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

200

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation

201

Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy

202

2021 Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

203

Real World Analysis of Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation- a RWE

204

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression

205

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy

206

Randomized Trial of Metoprolol in Patients with Obstructive Hypertrophic Cardiomyopathy

207

Dabigatran versus Warfarin on Cognitive Outcomes in Non- valvular Atrial Fibrillation: Results of the GIRAF Trial

208

AXIOMATIC-TKR Trial

209

Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE trial

210

Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 Trials

211

Real-World’ Prolonged DAPT Use Associated With Reduced Benefits, and Greater Harm

212

Rapid and Sustained Reversal of Ticagrelor–Intervention Trial called REVERSE-IT

213

Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation

214

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

215

Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

216

Association of Statin Therapy Initiation with Diabetes Progression

217

Metoprolol in Critically Ill Patients With COVID-19

218

Fineronone improves CV outcomes in T2DM with CKD 2-4 stages

219

Triglycerides and Residual Atherosclerotic Risk in participants with normal LDL-C levels

220

Antihypertensives and Statin Therapy for Primary Stroke Prevention (A Secondary Analysis of the HOPE-3 Trial).

221

Highlights of ESC Congress 2021: TOMAHAWK Trial

222

Highlights of ESC Congress 2021: STEP Study

223

Highlights of ESC Congress 2021: Master DAPT

224

Highlights of ESC Congress 2021: Emperor Preserved HF

225

Diabetes Duration Linked to Increasing Heart Failure Risk

226

Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting

227

Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial

228

Highlights of ESC HF 2021 - Insights from Augustus Trial

229

Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

230

Highlights of ESC HF 2021 - Insights from the VICTORIA trial (VerICiguaT global study in subjects with HFrEF)

231

Highlights of ESC HF 2021 - Insights from the GALACTIC-HF Trial

232

Highlights of ESC HF 2021 - Which Beta Blocker in HFmrEF?

233

PARADISE MI

234

THE ADAPTABLE STUDY

235

ATLANTIS

236

LAAOS 3

237

The Value of High-Sensitivity Troponin in the Era of COVID-19

238

Death and MI following initial revascularization versus optimal medical therapy in chronic coronary syndrome: A systemic review & Meta-analysis of RCT

239

Macitentan Triple combination therapy in Pulmonary Arterial Hypertension: Real World evidence from Opus Registry

240

The Future of Aspirin Therapy in Cardiovascular Disease